Thomas McFarlane

436 total citations
19 papers, 303 citations indexed

About

Thomas McFarlane is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Thomas McFarlane has authored 19 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Thomas McFarlane's work include Nausea and vomiting management (4 papers), CAR-T cell therapy research (4 papers) and Anesthesia and Pain Management (3 papers). Thomas McFarlane is often cited by papers focused on Nausea and vomiting management (4 papers), CAR-T cell therapy research (4 papers) and Anesthesia and Pain Management (3 papers). Thomas McFarlane collaborates with scholars based in Canada, Sweden and United States. Thomas McFarlane's co-authors include William Wong, Stephen Tully, Kelvin Chan, Edward Chow, John J. Kim, Erin McKenzie, Yasmeen Razvi, Carlo DeAngelis, Stephanie Chan and Pearl Zaki and has published in prestigious journals such as The Oncologist, Supportive Care in Cancer and Medical Decision Making.

In The Last Decade

Thomas McFarlane

19 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas McFarlane Canada 9 125 108 56 42 40 19 303
Scarlett Hao United States 10 110 0.9× 100 0.9× 61 1.1× 34 0.8× 31 0.8× 33 355
Katerina Zakka United States 12 191 1.5× 87 0.8× 58 1.0× 27 0.6× 62 1.6× 36 372
Faïza Khemissa France 8 149 1.2× 46 0.4× 60 1.1× 45 1.1× 87 2.2× 24 257
Kasper Jarlhelt Andersen Denmark 8 88 0.7× 101 0.9× 22 0.4× 111 2.6× 19 0.5× 25 300
Mohamed Ramdani France 6 123 1.0× 49 0.5× 78 1.4× 67 1.6× 101 2.5× 10 299
Alessandra Mele Italy 12 60 0.5× 130 1.2× 38 0.7× 28 0.7× 19 0.5× 29 331
Felicitas Lenz Germany 6 196 1.6× 135 1.3× 161 2.9× 17 0.4× 34 0.8× 8 421
Christine Yu United States 11 105 0.8× 83 0.8× 79 1.4× 16 0.4× 13 0.3× 26 321
Daisuke Kanda Japan 12 46 0.4× 101 0.9× 39 0.7× 76 1.8× 48 1.2× 55 371
Guido Müller Germany 8 51 0.4× 83 0.8× 61 1.1× 16 0.4× 24 0.6× 37 260

Countries citing papers authored by Thomas McFarlane

Since Specialization
Citations

This map shows the geographic impact of Thomas McFarlane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas McFarlane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas McFarlane more than expected).

Fields of papers citing papers by Thomas McFarlane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas McFarlane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas McFarlane. The network helps show where Thomas McFarlane may publish in the future.

Co-authorship network of co-authors of Thomas McFarlane

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas McFarlane. A scholar is included among the top collaborators of Thomas McFarlane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas McFarlane. Thomas McFarlane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Masucci, Lisa, Feng Tian, Stephen Tully, et al.. (2024). CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis. Medical Decision Making. 44(3). 296–306. 1 indexed citations
2.
Segal, Eve M., et al.. (2024). Review of drug-drug interactions in patients with prostate cancer. Journal of Oncology Pharmacy Practice. 30(6). 1057–1072. 3 indexed citations
3.
Henning, Jan‐Willem, et al.. (2023). Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective. Current Oncology. 30(8). 7672–7691. 3 indexed citations
4.
Wentzell, Jason, et al.. (2022). Clinical Pharmacy Services in Ambulatory Oncology: An Environmental Scan of the Canadian Practice Landscape. The Canadian Journal of Hospital Pharmacy. 75(4). 259–266. 2 indexed citations
5.
Boyd, Jamie M., et al.. (2022). Exploration of current pharmacy practice in cardio-oncology: Experiences & perspectives. Journal of Oncology Pharmacy Practice. 29(8). 1844–1852. 3 indexed citations
6.
Kim, Yong-Jin, et al.. (2021). Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Journal of Comparative Effectiveness Research. 10(3). 193–206. 5 indexed citations
7.
8.
Grindrod, Kelly, et al.. (2021). Understanding the Feasibility of Implementing Car T-Cell Therapies from a Canadian Perspective. Healthcare policy. 16(3). 89–105. 6 indexed citations
9.
Smith, Kelly M., et al.. (2021). A randomized controlled trial to assess the influence of a picture-based antiemetic medication calendar on medication-taking behavior in adults receiving chemotherapy. Journal of Oncology Pharmacy Practice. 28(8). 1763–1770. 3 indexed citations
10.
Kim, Yong-Jin, Mark Oremus, Helen Chen, et al.. (2020). Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncology. 16(27). 2045–2058. 10 indexed citations
11.
McLeod, Anne, et al.. (2019). Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone. Supportive Care in Cancer. 27(9). 3209–3217. 4 indexed citations
12.
McFarlane, Thomas, et al.. (2019). Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Annals of Palliative Medicine. 9(3). 1296–1306. 9 indexed citations
13.
McKenzie, Erin, Pearl Zaki, Srinivas Raman, et al.. (2019). Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Supportive Care in Cancer. 27(3). 783–791. 17 indexed citations
14.
McKenzie, Erin, Yasmeen Razvi, Thomas McFarlane, et al.. (2019). Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic. Supportive Care in Cancer. 27(9). 3245–3252. 8 indexed citations
15.
Tully, Stephen, Zeny Feng, Kelly Grindrod, et al.. (2019). Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model. JCO Clinical Cancer Informatics. 3(3). 1–9. 23 indexed citations
16.
Kim, John J., Thomas McFarlane, Stephen Tully, & William Wong. (2019). Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis. The Oncologist. 25(3). e512–e519. 53 indexed citations
17.
Richard, Cynthia L., et al.. (2018). Impact and Attitudes about Peer Review of Teaching in a Canadian Pharmacy School. American Journal of Pharmaceutical Education. 83(6). 6828–6828. 10 indexed citations
18.
Razvi, Yasmeen, Stephanie Chan, Thomas McFarlane, et al.. (2018). ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Supportive Care in Cancer. 27(1). 87–95. 104 indexed citations
19.
McFarlane, Thomas, et al.. (2017). Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist. 23(2). 225–233. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scarlett Hao Breakdown of academic impact, for papers by Katerina Zakka Breakdown of academic impact, for papers by Faïza Khemissa Breakdown of academic impact, for papers by Kasper Jarlhelt Andersen Breakdown of academic impact, for papers by Mohamed Ramdani Breakdown of academic impact, for papers by Alessandra Mele Breakdown of academic impact, for papers by Felicitas Lenz Breakdown of academic impact, for papers by Christine Yu Breakdown of academic impact, for papers by Daisuke Kanda Breakdown of academic impact, for papers by Guido Müller
Rankless by CCL
2026